This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2005 Mar 1;191(5):647-9.

doi: 10.1086/428406. Epub 2005 Jan 27.

Lessons from failure--preparing for future HIV-1 vaccine efficacy trials

Barney S Graham, John R Mascola

PMID: 15688276
DOI: 10.1086/428406

Editorial

Lessons from failure--preparing for future HIV-1 vaccine efficacy trials

Barney S Graham et al. J Infect Dis. 2005.

. 2005 Mar 1;191(5):647-9.

doi: 10.1086/428406. Epub 2005 Jan 27.

Authors

Barney S Graham, John R Mascola

PMID: 15688276
DOI: 10.1086/428406

No abstract available

PubMed Disclaimer

Comment on

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.
Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF; rgp120 HIV Vaccine Study Group. Flynn NM, et al. J Infect Dis. 2005 Mar 1;191(5):654-65. doi: 10.1086/428404. Epub 2005 Jan 27. J Infect Dis. 2005. PMID: 15688278 Clinical Trial.
Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial.
Gilbert PB, Peterson ML, Follmann D, Hudgens MG, Francis DP, Gurwith M, Heyward WL, Jobes DV, Popovic V, Self SG, Sinangil F, Burke D, Berman PW. Gilbert PB, et al. J Infect Dis. 2005 Mar 1;191(5):666-77. doi: 10.1086/428405. Epub 2005 Jan 27. J Infect Dis. 2005. PMID: 15688279 Clinical Trial.

Similar articles

Controversial HIV vaccine enters phase III trials amid skepticism.
[No authors listed] [No authors listed] AIDS Alert. 1998 Dec;13(12):133-4, 136. AIDS Alert. 1998. PMID: 11366059
Public health. A sound rationale needed for phase III HIV-1 vaccine trials.
Burton DR, Desrosiers RC, Doms RW, Feinberg MB, Gallo RC, Hahn B, Hoxie JA, Hunter E, Korber B, Landay A, Lederman MM, Lieberman J, McCune JM, Moore JP, Nathanson N, Picker L, Richman D, Rinaldo C, Stevenson M, Watkins DI, Wolinsky SM, Zack JA. Burton DR, et al. Science. 2004 Jan 16;303(5656):316. doi: 10.1126/science.1094620. Science. 2004. PMID: 14726576 No abstract available.
Funding support lacking in search for HIV vaccine.
[No authors listed] [No authors listed] AIDS Alert. 1999 Jan;14(1):5-7. AIDS Alert. 1999. PMID: 11366091
Therapeutic vaccine trails in Thailand.
Churdboonchart V. Churdboonchart V. J HIV Ther. 2004 Sep;9(3):57-9. J HIV Ther. 2004. PMID: 15534562 Review.
The challenges of HIV vaccine development and testing.
Burgers WA, Williamson C. Burgers WA, et al. Best Pract Res Clin Obstet Gynaecol. 2005 Apr;19(2):277-91. doi: 10.1016/j.bpobgyn.2004.11.001. Best Pract Res Clin Obstet Gynaecol. 2005. PMID: 15778116 Review.

See all similar articles

Cited by

Augmented designs to assess immune response in vaccine trials.
Follmann D. Follmann D. Biometrics. 2006 Dec;62(4):1161-9. doi: 10.1111/j.1541-0420.2006.00569.x. Biometrics. 2006. PMID: 17156291 Free PMC article.
Traitors of the immune system-enhancing antibodies in HIV infection: their possible implication in HIV vaccine development.
Beck Z, Prohászka Z, Füst G. Beck Z, et al. Vaccine. 2008 Jun 6;26(24):3078-85. doi: 10.1016/j.vaccine.2007.12.028. Epub 2008 Jan 10. Vaccine. 2008. PMID: 18241961 Free PMC article. Review.
Inhibition of HIV-1 entry by antibodies: potential viral and cellular targets.
Phogat S, Wyatt RT, Karlsson Hedestam GB. Phogat S, et al. J Intern Med. 2007 Jul;262(1):26-43. doi: 10.1111/j.1365-2796.2007.01820.x. J Intern Med. 2007. PMID: 17598813 Free PMC article. Review.
Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications.
Buonaguro L, Tornesello ML, Buonaguro FM. Buonaguro L, et al. J Virol. 2007 Oct;81(19):10209-19. doi: 10.1128/JVI.00872-07. Epub 2007 Jul 18. J Virol. 2007. PMID: 17634242 Free PMC article. Review. No abstract available.
Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses.
Koup RA, Roederer M, Lamoreaux L, Fischer J, Novik L, Nason MC, Larkin BD, Enama ME, Ledgerwood JE, Bailer RT, Mascola JR, Nabel GJ, Graham BS; VRC 009 Study Team; VRC 010 Study Team. Koup RA, et al. PLoS One. 2010 Feb 2;5(2):e9015. doi: 10.1371/journal.pone.0009015. PLoS One. 2010. PMID: 20126394 Free PMC article. Clinical Trial.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information